TABLE 3.

Metabolites with differences in levels between the onset of symptoms and the defervescence phase with the most power to discriminate ND subjects and DENV-infected subjects according to sPLS-DA pairwise multivariate statistics^a

^asPLS-DA pairwise models of uncertainty and validity were assessed by plotting the classification error rate as a function of the number of components based on the leave-one-out validation strategy. For all models, error rates were below 10% (see Fig. S1 in the supplemental material). ↑, an increase in the plasma metabolite concentration in the defervescence phase of the disease compared to that at the onset of symptoms for each group; ↓, a decrease in the plasma metabolite concentration in the defervescence phase of the disease compared to that at the onset of symptoms for each group; –, metabolites that did not contribute to the discrimination of groups; BCAA, branched-chain amino acids; ND, nondengue patients; DFp, patients with primary infection presenting as dengue fever; DFs, patients with secondary infection presenting as dengue fever; DHFp, patients with primary infection presenting as dengue hemorrhagic fever; DHFs, patients with secondary infection presenting as dengue hemorrhagic fever.